Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for pulmonary inflammatory and fibrogenic activity reduction in silicosis with progressive massive fibrosis
2021-002701-94Phase 2Active
- Sponsor
- Fundación para la Gestión de la Investigación Biomédica de Cádiz
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pirfenidone in silicosis and progressive massive fibrosis (PMF), sponsored by Fundación para la Gestión de la Investigación Biomédica de Cádiz. Primary endpoint: Primary: Cell biomarkers in peripheral blood. Started Jun 2021; status: active.
02
Drugs
pirfenidone
03
Conditions
silicosisprogressive massive fibrosis (PMF)
Beyond the preview
Go deeper on 2021-002701-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002701-94.